March 2024 • PharmaTimes Magazine • 36-37
// YOUR MOVES //
Your Moves
Mover of the Month
Wilmington Healthcare has announced that Julian Snape has taken on the role of Head of Consultancy.
With over 30 years of experience in the UK life sciences industry, Julian's expertise lies in his specialist UK Healthcare market insight. This will help him spearheading the company’s mission to improve patient pathways and support the NHS.
Throughout his career, Julian has successfully delivered over 500 business transformation and optimisation projects across the UK and 19 other countries.
He has honed his skills in commercial effectiveness and strategic planning roles within pharma, implementing innovative data strategies and pioneering go-to-market approaches that enable clients to optimise the performance of their assets.
“I’m excited to head up this hugely experienced consultancy team, and looking forward to working with pharma on a range of business-critical areas, especially commercial optimisation and providing unique go-to-market insight about the UK healthcare sector”, Julian says.
Meanwhile the company has also announced the appointment of Sarah Hawkins as Operations Director.
Sarah has worked in B2B strategic marketing for over 30 years across a variety of industries including legal and finance.
She has spent the last 18 years at Wilmington Healthcare focusing on healthcare marketing, and more recently pharmaceutical marketing.
She will now lead customer data optimisation and service excellence across the whole of the WH portfolio including data/CRM, omnichannel marketing, subscription services, HSJ and other associated services.
She says: “It’s great to have the opportunity to work more closely with our pharmaceutical clients across a wider remit. I’m passionate about providing optimal service and delivery of our products and services that many of our clients rely on for business growth and success.”
Enhanc3D Genomics has announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).
Daniel’s experience in genomics technology development and commercialisation will be key to achieving the next phase of Enhanc3D Genomics’ growth.
As CSO Daniel will be driving Enhanc3D Genomics’ scientific strategy, extending the GenLink3D technology into next-generation versions that require only minimal, or even single cell-level, inputs. He will also be building additional commercial and academic partnerships for the development of candidate therapeutic targets identified from the GenLink3D platform.
Daniel has over 20 years of senior leadership experience within the fields of genetics, molecular biology and sequencing research.
He joins Enhanc3D Genomics from Oxford Nanopore Technologies, where he held roles including Senior Vice President, Vice President and Senior Director of Applications.
During his more than 13 years with Oxford Nanopore he established various strategic collaborations and led projects to demonstrate the range of applications of the company’s technology.
Daniel was also previously Head of Sequencing Technology Development at the Wellcome Trust Sanger Institute, following postdoctoral roles at Wellcome Sanger and at Weill Cornell Medical College.
Arecor Therapeutics has announced the appointment of Dr Helen Parris as Senior Vice President, Commercial and General Manager of the Group’s subsidiary company, Tetris Pharma.
Helen has over 20 years of scientific, commercial and government affairs experience across several international biopharmaceutical companies and has been responsible for launching transformational products and shaping markets across large pharmaceutical and biotechnology companies.
Prior to joining Tetris, Helen served as General Manager Northern Markets at Albireo Pharma, which was acquired by Ipsen in 2023, and where she played a key role in establishing and building the regional affiliate and launching the first product to market.
Previously, Helen held multiple positions at Gilead, including Executive Director EMEA, Global Affairs Regional Lead, and was instrumental in broadening patient access to treatment.
While at Gilead, Helen led the launch of several transformational drugs, developed critical launch strategies and expanded commercial opportunities.
OneChain Immunotherapeutics (OCI) has announced Stefanos Theoharis as the company's new Chief Executive Officer. He succeeds Jorge Alemany, who has served as CEO since the creation of the company in June 2020 and will now retire.
Stefanos has more than twenty years of experience in the field of cell and gene therapy, business development, programme management and manufacturing.
His career includes key roles such as Chief Business Officer at Bone Therapeutics, a Belgium-based company specialising in cell therapies for orthopaedic disorders, Senior Vice President at Cell Medica and Chief Business Officer at Apceth Biopharma.
He also held positions as Business Development Director at the antisense RNA drug company Isarna, and Business Development Director at Roche, focused on partnering activities for emerging technologies. Stefanos explained: “What truly excites me about this position is that the company is young enough to have a significant potential for growth and development yet mature enough to have established a solid track record.”
SPT Labtech is pleased to announce the appointment of Morten Frost Norgreen as Chief Commercial Officer.
In this newly created position, Morten will spearhead SPT Labtech’s commitment to understanding and exceeding customer expectations, and will lead the group’s teams to create solutions to enable more productive scientific research and diagnostic workflows.
Morten joins SPT Labtech from Veracyte Inc, where he served as the Chief Commercial Officer, IVD. His extensive background also includes senior leadership roles at Agilent Technologies and IQVIA.
With substantial experience across clinical, diagnostics and genomics markets, he has successfully delivered revenue growth through effective execution of go-to-market strategies.
Morten Frost Norgreen adds, "I am honoured to be part of a group with such a strong reputation for innovation and excellence. I look forward to joining a great team and continuing the momentum that has been created through a relentless focus on delivering value to our customers.”
Stirred has announced the arrival of former Evoke consumer health director, Amy Greenwood, to lead its new offering, Stirred Well.
Amy arrives directly from Evoke (formerly Pegasus), where she oversaw its consumer health portfolio, which included clients such as Thornton & Ross, Superdrug, Perrigo and Galderma.
Stirred Well will support Stirred’s mission to drive real-world health outcomes, by extending its reach into the increasingly important preventative, everyday health space.
Amy’s arrival sees her reunite with Stirred co-founders and former Pegasus board directors, Stuart Hehir and Jo Spadaccino, with whom she worked between 2008-2020.
Amy elaborated: “At Stirred Well we’re not only on top of changing consumer behaviours and the complex retailer landscape, but as a specialist health agency, we have a deep understanding of wider health systems and how they impact the wellness market. This puts us in a great position to build compelling and impactful campaigns, as well as advise on trends and opportunities coming down the line.”
SpliceBio has announced the appointment of Aniz Girach as Chief Medical Officer. Aniz is an ophthalmologist with over 25 years of industry experience in the area of Medical Retina and Genetic Therapy for inherited retinal diseases.
He has been involved in the development and approval of four drugs in ophthalmology. Dr Girach was Global Head of Ophthalmology at Merck & Co and Vice President, Clinical Development at Alcon Laboratories.
At Oxurion he was Global Head of Ophthalmology and Chief Medical Officer where he oversaw the development and approval of Ocriplasmin – a first-in-class biologic therapy for retinal disease.
He was also Chief Medical Officer at Nightstar Therapeutics where he led and oversaw the development of its gene therapy programmes for inherited retinal diseases, prior to its acquisition by Biogen for $800 million.
Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics as its Chief Medical Officer.
Ferrer has announced the appointment of Olaf Gerber as its Country Manager for Germany.
Olaf will be based in Herzogenrath and will oversee the implementation of Ferrer’s strategic plan for 2024-2028, to support the company’s development in the German market and to launch innovative product lines in the country. He succeeds Amina Elsner, who has been appointed head of medical affairs for North-East Europe.
He brings over 30 years of experience in the pharmaceutical industry and has worked in various roles across sales, marketing and strategy at local, regional and global levels.
He also has expertise across multiple therapeutic areas, including several benchmark launches, within different market access environments.
Olaf has spent most of his career at Bayer. Most recently, he served as managing director at Jenapharm, a German Bayer subsidiary.
He is passionate about his team’s personal and professional development, the evolution of the go-to-market model and fostering innovation.